Name:
Institution:
Type:
PI
Grant Award Details
Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes
Grant Type:
Grant Number:
DISC2-11175
Project Objective:
In vivo validation of therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes that incorporate a safety kill switch.
Investigator:
Disease Focus:
Diabetes
Metabolic Disorders
Type 1 diabetes
Human Stem Cell Use:
Embryonic Stem Cell
Cell Line Generation:
Embryonic Stem Cell
Award Value:
$1,637,209
Status:
Closed
Progress Reports
Reporting Period:
Year 2
View Report
Grant Application Details
Application Title:
- Therapeutic immune tolerant human islet-like organoids (HILOs) for Type 1 Diabetes
Public Abstract:
Research Objective
Development of immune tolerant human islet-like organoids for transplantation into diabetic patients.
Impact
Our proposal will progress the development of an unlimited, reproducible source of immune tolerant engineered islets for transplantation into Type I diabetics.
Major Proposed Activities
- Demonstrate efficacy of immune tolerant HILOs in humanized diabetic mice
- Demonstrate safety of immune tolerant HILOs
- Incorporate a “kill switch” into immune tolerant HILOs
Statement of Benefit to California:
Diabetes affects 3 million people in California. Type 1 diabetes is a particular burden as it requires life-long administration of insulin. Allo- transplantation of islets is limited by availability of donor cells. This proposal will progress the development of functional islet-like organoids as an unlimited, reproducible source by engineering in immune tolerance to enhance and prolong functionality and survival upon transplantation into diabetic patients.
Publications
- Nature (2020) Immune-evasive human islet-like organoids ameliorate diabetes. (PubMed: 32814902)
